【摘要】 目的观察吉非替尼片联合康莱特胶囊治疗ⅢB/Ⅳ期存在表皮生长因子受体(EGFR)敏感突变的非小细胞肺癌患者的临床疗效及安全性。方法将80例ⅢB/Ⅳ期存在EGFR敏感突变的非小细胞肺癌患者随机分为对照组40例和试验组40例。对照组予以吉非替尼250 mg·d-1,qd,口服;试验组在对照组治疗的基础上,予以康莱特胶囊每次2.7 g,qid,口服。2组患者均治疗至肿瘤进展或患者不能耐受。比较2组患者的临床疗效和药物不良反应的发生情况。结果治疗后,试验组和对照组的总有效率分别为17.50%(7/40例)和7.50%(3/40例),疾病控制率分别为92.50%(37/40例)和87.50%(35/40例),无进展生存时间分别为17.70个月和16.30个月,差异均无统计学意义(均P>0.05)。试验组的药物不良反应主要有腹泻、皮疹、食欲缺乏等,对照组的药物不良反应主要有腹泻、皮疹、恶心等。试验组与对照组的总药物不良反应发生率分别为60.00%和85.00%,差异有统计学意义(P<0.05)。结论吉非替尼片联合康莱特胶囊治疗ⅢB/Ⅳ期非小细胞肺癌能显著降低药物不良反应的发生率,且存在延长疾病进展时间的趋势。更多还原

【Abstract】 Objective To observe the clinical efficacy and safety of gefitinib tablets combined with Kanglaite capsules in the treatment of stageⅢB/Ⅳ non-small cell lung cancer( NSCLC) with epidermal growth factor receptor( EGFR) sensitive mutations. Methods Eighty patients of stage Ⅲ B/Ⅳ NSCLC with EGFR sensitive mutations were randomly divided into control group and treatment group with 40 cases per group.Control group was given gefitinib 250 mg · d-1,qd,oral. Treatment group received Kanglaite capsule 2. 7 mg,qid,oral,on the basis of control group. Two groups were treated to tumor progression or intolerant.The clinical efficacy and adverse drug reactions were compared between two groups. Results After treatment,the total effective rates in control and treatment groups were 17. 50%( 7/40 cases) and 7. 50%( 3/40 cases),disease control rates( DCR) in control and treatment groups were92. 50%( 37/40 cases) and 87. 50%( 35/40 cases),progress free survival in control and treatment groups were 17. 7 months and 16. 3months,the differences were statistically significant( all P > 0. 05). The adverse drug reactions in treatment group were based on diarrhea,rashand loss of appetite,which in control group were based on diarrhea,rash and nausea. The incidences of adverse drug reactions in treatment and control groups were 60. 00% and 85. 00% with significant difference( P < 0. 05).Conclusion Gefitinib tablet combined with Kanglaite capsule can reduce the incidence of adverse drug reaction,and maybe extend the progress free survival.更多还原